---
aliases: [JNJ, J&J]
---
#actor #pharma #medtech #usa #public

**Johnson & Johnson** — Pharma + MedTech giant. ~$94B revenue. DARZALEX, TREMFYA. Post-consumer spinoff.

---

## Why J&J matters

| Metric | Value |
|--------|-------|
| Ticker | JNJ |
| Market cap | ~$500B |
| 2025E revenue | **~$94B** |
| Segments | Innovative Medicine, MedTech |
| Stock YTD | +38-40% |

---

## 2025 financial performance

| Quarter | Revenue | YoY |
|---------|---------|-----|
| Q3 2025 | $24.0B | +6.8% |
| TTM | $92.1B | +5.1% |
| FY25E | ~$93.7B | +5.7% |

---

## Business segments

| Segment | Q3 2025 | Growth drivers |
|---------|---------|----------------|
| **Innovative Medicine** | $15.6B | DARZALEX, TREMFYA, CARVYKTI |
| **MedTech** | $8.4B | Electrophysiology, Abiomed |

---

## Key drugs

| Drug | Indication | Status |
|------|------------|--------|
| **DARZALEX** | Multiple myeloma | Blockbuster |
| **TREMFYA** | Immunology | Growing |
| **CARVYKTI** | CAR-T cancer | Growing |
| **STELARA** | Immunology | Biosimilar pressure |
| **ERLEADA** | Prostate cancer | Growing |
| **SPRAVATO** | Depression | Neuroscience leader |

---

## Kenvue spinoff (2023)

| Detail | Value |
|--------|-------|
| Spun off | [[Consumer]] health |
| New company | Kenvue (KVUE) |
| Brands | Tylenol, Band-Aid, Neutrogena |
| J&J focus | Pharma + MedTech only |

---

## Challenges

| Issue | Impact |
|-------|--------|
| STELARA biosimilars | ~1,070 bps headwind |
| Talc litigation | Ongoing settlement |
| Tariffs | ~$400M impact (MedTech) |

---

## TCJA repatriation (2018)

J&J repatriated significant overseas cash under the [[Tax Cuts and Jobs Act]] one-time tax holiday. Deployed into diversified purposes including M&A and dividends.

---

## Investment case

**Bull:**
- Diversified pharma + MedTech
- DARZALEX, CARVYKTI growth
- MedTech recovery (EP, Abiomed)
- Dividend aristocrat
- Post-Kenvue focus

**Bear:**
- STELARA biosimilar cliff
- Talc litigation overhang
- Patent expirations
- Tariff exposure
- Mature growth profile

---


![[jnj-employees-chart.png]]
*Headcount: 138,200 (2025) — up 0.1% YoY*

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | JNJ |
| 2025E revenue | ~$94B |
| Market cap | ~$500B |
| Focus | Pharma + MedTech |

---

## Related

- [[Biopharma]] — sector
- [[Eli Lilly]] — pharma peer
- [[Pfizer]] — pharma peer
- [[Medtronic]] — MedTech peer
- [[Tax Cuts and Jobs Act]] — repatriation (2018)

---

## Sources

- [J&J Q3 2025](https://www.investor.jnj.com/investor-news/news-details/2025/Johnson--Johnson-Reports-Q3-2025-Results-Raises-2025-Sales-Outlook/)

*Created 2026-01-09*
